Unprecedented in vivo activity of telacebec against Mycobacterium leprae
We demonstrated that monotherapy of TCB exhibited bactericidal activity against M. leprae comparable to that of MDT and that all combination therapies were as effective as MDT, except the combination TCB + CFZ, possibly due to an antagonism between these two drugs.
Authors
- Emmanuelle Cambau (ORCID: https://orcid.org/0000-0001-5944-2530)
- Nicolas Véziris (ORCID: https://orcid.org/0000-0001-5660-6544)
- Aurélie Chauffour (ORCID: https://orcid.org/0000-0002-8846-5069)
- Kévin Pethe (ORCID: https://orcid.org/0000-0003-0916-8873)
- Alexandra Aubry (ORCID: https://orcid.org/0000-0003-4230-4793)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Nanyang Technological University (SG)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire National de Référence (MA)
- Centre d'Immunologie et des Maladies Infectieuses (FR)
- CNR de la Résistance aux Antibiotiques (FR)
- Singapore Centre for Environmental Life Sciences Engineering (SG)
- Hôpital Bichat-Claude-Bernard (FR)
- National Centre for Infectious Diseases (SG)
Publication Details
- Journal
- PLoS neglected tropical diseases
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1371/journal.pntd.0013076
- Citations
- 2
- Primary Topic
- Leprosy Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Fondation Raoul Follereau